Compare · MBX vs NVO
MBX vs NVO
Side-by-side comparison of MBX Biosciences Inc. (MBX) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MBX and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $200.72B, about 67.7x MBX ($2.97B).
- Over the past year, MBX is up 314.6% and NVO is down 19.6% - MBX leads by 334.2 points.
- NVO has been more active in the news (8 items in the past 4 weeks vs 5 for MBX).
- NVO has more recent analyst coverage (25 ratings vs 13 for MBX).
- Company
- MBX Biosciences Inc.
- Novo Nordisk A/S
- Price
- $60.58-1.60%
- $45.33+0.00%
- Market cap
- $2.97B
- $200.72B
- 1M return
- -5.95%
- -3.75%
- 1Y return
- +314.65%
- -19.59%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2024
- News (4w)
- 5
- 8
- Recent ratings
- 13
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest MBX
- MBX Biosciences Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- MBX Biosciences Announces First Patient Dosed in Pivotal Phase 3 oPTimize Trial of Once-Weekly Canvuparatide in Adults with Hypoparathyroidism
- Analyst resumed coverage on MBX Biosciences with a new price target
- SEC Form 144 filed by MBX Biosciences Inc.
- Amendment: SEC Form SCHEDULE 13D/A filed by MBX Biosciences Inc.
- SEC Form 10-Q filed by MBX Biosciences Inc.
- MBX Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- MBX Biosciences Reports Second Quarter 2026 Financial Results and Corporate Highlights
- Chief Medical Officer Azoulay Salomon sold $24,335 worth of shares (370 units at $65.77), decreasing direct ownership by 3% to 14,399 units (SEC Form 4) to satisfy withholding obligation
- SEC Form 144 filed by MBX Biosciences Inc.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Deutsche Bank
- SEC Form 6-K filed by Novo Nordisk A/S
- A New Category Is Forming in Medical Aesthetics. Independent Research Has Started Sizing It.
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Berenberg
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S